1Berndt ER. Pharmaceuticals in U.S. health care determinants of quantity, and price[J]. Journal of Economic Perspectives, 2002,16 (4): 45-66.
2Kremer M. Pharmaceuticals and the developing world[J]. Journal of Economic Perspectives, 2002, 16(4): 67-90.
3Levit K, Smith C. Health spending rebound continues in 2002[J]. Health Affairs, 2004, 23(1): 147-159.
4Mrazek MF. Comparative approaches to pharmaceutical price regulation in the european union[J]. Croatian Medical Journal, 2002, 43(4): 453-61.
5Bloor K, Maynard A, Freemantle N. Lessons form international experience in controlling pharmaceutical expenditure[J]. British Medical Journal, 1996, 312(7 045): 1 525.
6Giovanni G. The german experience in reference pricing[J]. Health Policy, 1998(44): 73-85.
7Addis A, Magrini N. New approaches toanalyzing prescription data and transfer pharmacoepidemiological and evidence-based reports to prescriberes[J]. Pharmacoepidemiology and Drug Safety, 2002(11)- 721-726.
8The Kaiser Family Foundation. Prescription drug trends: a chartbook update[R]. 2001.
9Heftier S. Health spending growth up in 1999, Faster growth expected in the future[J]. Health Affairs, 2001, 20(2): 193-203.
10Barents Group. Factors affecting the growth of prescription drug expenditures[R]. 1999.
